Dermata Therapeutics, Inc.(NASDAQ:DRMA) 
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clin...
Website: https://www.dermatarx.com
Founded: 2014
IPO Price: $7 (Aug 13, 2021)
Full Time Employees: 8
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 9.20
H 9.70
L 8.80
C 9.60
V 173,917
10EMA 9.60
20EMA 9.60
60EMA 9.60
120EMA 9.60
250EMA 9.60